PDS Biotechnology gets FDA fast track status for PDS0101

pallavi123- June 5, 2022 0

PDS Biotechnology has secured fast track designation to its PDS0101 in combination with Merck’s KEYTRUDA (pembrolizumab) from the US Food and Drug Administration (FDA) for ... Read More

Here’s why the body may reject lung transplants

pharmanewsdaily- March 5, 2019 0

New Delhi, Mar 05 (ANI): A study led by researchers at Washington University School of Medicine in St. Louis, has identified, in mice, a process ... Read More